AU2002241533A1 - Cytonkine receptor zcytor19 - Google Patents

Cytonkine receptor zcytor19

Info

Publication number
AU2002241533A1
AU2002241533A1 AU2002241533A AU4153302A AU2002241533A1 AU 2002241533 A1 AU2002241533 A1 AU 2002241533A1 AU 2002241533 A AU2002241533 A AU 2002241533A AU 4153302 A AU4153302 A AU 4153302A AU 2002241533 A1 AU2002241533 A1 AU 2002241533A1
Authority
AU
Australia
Prior art keywords
polypeptides
zcytor19
receptor
methods
vitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002241533A
Inventor
Francis J Grant
Julia E. Novak
Scott R. Presnell
Theodore E. Whitmore
Wen-Feng Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of AU2002241533A1 publication Critical patent/AU2002241533A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Abstract

Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
AU2002241533A 2000-11-28 2001-11-28 Cytonkine receptor zcytor19 Abandoned AU2002241533A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25356100P 2000-11-28 2000-11-28
US60/253,561 2000-11-28
US26721101P 2001-02-07 2001-02-07
US60/267,211 2001-02-07
PCT/US2001/044808 WO2002044209A2 (en) 2000-11-28 2001-11-28 Cytonkine receptor zcytor19

Publications (1)

Publication Number Publication Date
AU2002241533A1 true AU2002241533A1 (en) 2002-06-11

Family

ID=26943370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002241533A Abandoned AU2002241533A1 (en) 2000-11-28 2001-11-28 Cytonkine receptor zcytor19

Country Status (12)

Country Link
US (10) US20030027253A1 (en)
EP (1) EP1356046B1 (en)
JP (1) JP2004532611A (en)
AT (1) ATE445701T1 (en)
AU (1) AU2002241533A1 (en)
CA (1) CA2430485A1 (en)
CY (1) CY1110921T1 (en)
DE (1) DE60140213D1 (en)
DK (1) DK1356046T3 (en)
ES (1) ES2334888T3 (en)
PT (1) PT1356046E (en)
WO (1) WO2002044209A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027253A1 (en) 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
TW200300170A (en) * 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
EP1497415B1 (en) 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
US7157559B2 (en) 2003-08-07 2007-01-02 Zymogenetics, Inc. Homogeneous preparations of IL-28 and IL-29
US7381794B2 (en) 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
BRPI0513865A (en) 2004-07-29 2008-05-20 Zymogenetics Inc methods for treating cancer, inhibiting the progression of cancer, delaying the onset of cancer, reducing the severity of cancer, and inhibiting at least one of the conditions or symptoms of cancer, non-hodgkin lymphoma, multiple myeloma, and of tumors of the head and neck
WO2007013830A1 (en) 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PT2124947T (en) 2007-01-31 2017-10-25 BIAL-PORTELA & Cª S A Dosage regimen for comt inhibitors
CA2704038A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
CA2757418C (en) * 2009-04-01 2021-06-15 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
CA2757411C (en) 2009-04-01 2017-06-27 Teofilo Cardoso De Vasconcelos Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US20140193876A1 (en) * 2011-06-13 2014-07-10 Aaron R. Goerke Methods of purification of native or mutant forms of diphtheria toxin
CA2858025C (en) 2011-12-13 2020-09-22 Bial-Portela & Ca., S.A. 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-2-hydroxy-3-methoxy-1-nitrobenzene as an intermediate to prepare a catechol-o-methyltransferase inhibitor
AU2014240012A1 (en) * 2013-03-15 2015-09-24 Abbvie Inc. Antibody drug conjugate (ADC) purification
TW201446961A (en) 2013-05-06 2014-12-16 Abbvie Inc Compositions for cell culture and methods of using the same
WO2016033509A1 (en) * 2014-08-29 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
JP2018500300A (en) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． Medicines for delaying Parkinson's disease
EP3442567A4 (en) * 2016-04-13 2019-12-18 Orimabs Ltd. Anti-psma antibodies and use thereof
WO2023049774A1 (en) * 2021-09-21 2023-03-30 University Of Washington Genetically encoded and exogenously triggered protein-protein ligation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU6069300A (en) 1999-07-02 2001-01-22 Chiron Corporation Novel human genes and gene expression products
US7060800B2 (en) * 2000-09-08 2006-06-13 Schering Corporation Antibodies binding the TNF related protein, TNF-X
US20030027253A1 (en) 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
EP1501936B1 (en) * 2001-04-20 2008-08-06 ZymoGenetics, Inc. Cytokine protein family
JPWO2003031620A1 (en) 2001-10-02 2005-01-27 持田製薬株式会社 Novel class II cytokine receptor
TW200300170A (en) * 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
WO2003066002A2 (en) 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
EP1497415B1 (en) * 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
CA2503305A1 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
US20060228710A1 (en) 2003-02-14 2006-10-12 Morris David W Novel therapeutic targets in cancer

Also Published As

Publication number Publication date
US7608452B2 (en) 2009-10-27
US20110091876A1 (en) 2011-04-21
CY1110921T1 (en) 2015-06-10
US20070048799A1 (en) 2007-03-01
US20070048804A1 (en) 2007-03-01
PT1356046E (en) 2010-03-09
US20140248661A1 (en) 2014-09-04
CA2430485A1 (en) 2002-06-06
US20050266485A1 (en) 2005-12-01
WO2002044209A3 (en) 2003-08-21
DE60140213D1 (en) 2009-11-26
US20070048846A1 (en) 2007-03-01
ATE445701T1 (en) 2009-10-15
DK1356046T3 (en) 2010-03-01
JP2004532611A (en) 2004-10-28
US20030027253A1 (en) 2003-02-06
US20070117165A1 (en) 2007-05-24
EP1356046B1 (en) 2009-10-14
EP1356046A2 (en) 2003-10-29
US20120064571A1 (en) 2012-03-15
US7618791B2 (en) 2009-11-17
US20070111942A1 (en) 2007-05-17
ES2334888T3 (en) 2010-03-17
US7601809B2 (en) 2009-10-13
WO2002044209A2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
AU2002241533A1 (en) Cytonkine receptor zcytor19
WO2002000721A3 (en) Cytokine receptor zcytor17
AU2001253127A1 (en) Soluble zalpha11 cytokine receptors
NZ510744A (en) Cytokine receptor zalpha11
UA84387C2 (en) Human cytokine as a ligand of zalpha receptor and use thereof
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
AU3009397A (en) Hematopoietic cytokine receptor
HK1008230A1 (en) Tie-2 ligands, methods of making and uses thereof.
IL163067A (en) Isolated heterodimeric cytokine receptor
WO2003060090A3 (en) Novel cytokine zcytor17 ligand
MXPA02002384A (en) Fibroblast growth factor like polypeptides.
MXPA05008521A (en) Antibodies to c-met for the treatment of cancers.
IL110672A0 (en) Therapeutic heterocycles
NO971341D0 (en) Promoter for receptor tyrosine kinase TIE
MXPA02008239A (en) Human schizophrenia gene.
MXPA03000227A (en) Novel compounds.
PT877803E (en) PROTEIN RECEPTOR OB AND COMPOSITIONS AND RELATED METHODS
WO2003089603A3 (en) Cytokine receptor
HK1025793A1 (en) Hepatitis c receptor protein cd81
TR200000416T2 (en) Neisseria loctoferrin binding protein.
DE60117788D1 (en) HUMAN WINGLESS-ENOUGH GENES
EP1736545A3 (en) Soluble zcytor 11 cytokine receptors